Ofatumumab

mAbs

Volumn 1, Issue 4, 2009, Pages 326-331

  Zhang, Bodi ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

CD20; Chronic lymphocytic leukemia; Monoclonal antibody; Multiple sclerosis; Rheumatoid arthritis

Indexed keywords

AFUTUZUMAB; ALEMTUZUMAB; CD20 ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; METHOTREXATE; MONOCLONAL ANTIBODY; OCTELIZUMAB; OFATUMUMAB; PLACEBO; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VELTUZUMAB; VINCRISTINE;

ANTIGEN BINDING; B CELL LYMPHOMA; B LYMPHOCYTE; BINDING AFFINITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CYTOLYTIC HEPATITIS; CYTOTOXICITY; DISEASE COURSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FOLLICULAR LYMPHOMA; HERPES ZOSTER; HUMAN; INTERSTITIAL PNEUMONIA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHEUMATOID ARTHRITIS; SEVERE COMBINED IMMUNODEFICIENCY; SHORT SURVEY; SURVIVAL RATE; TRANSGENIC ANIMAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WALDENSTROEM MACROGLOBULINEMIA;

EID: 77953677610     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.4.8895     Document Type: Short Survey

References (22)

1. Alexander DD, Mink PJ, Adami HO, Chang ET, Cole P, Mandel JS, et al. The non-Hodgkin lymphomas: A review of the epidemiologic literature. Int J Cancer 2007; 120:1-39. (Pubitemid 46732571)
2. Cavenagh JD, Lister TA. Chronic lymphocyte leukemia. Diagnosis and management. Chronic Leukemias and Lymphomas. Biology, Pathophysiology and Clinical Management (Ed: Schiller GJ) Humana Press Inc., Totova, New Jersey 2003; 23-53.
3. Nikbin B, Bonab MM, Khosravi F, Talebian F. Role of B cells in pathogenesis of multiple sclerosis Int Rev Neurobiol 2007; 79:13-42.
4. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand 1940; 17:172-188
5. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-497
6. Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001; 40:205-211 (Pubitemid 32229642)
7. Leandro MJ, Edwards JCW, Cambridge G. Clinical outcome in 22 patients with RA treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61:1-5.
8. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999; 134:445-450
9. 2+ conductance found constitutively in B-lymphocytes. J Cell Biol 1993; 121:1121-1132
10. Kosmas C, Stamatopoulos K, Stavroyianni N, Tsavaris N, Papadaki T. Anti-CD20-based therapy of B cell lymphoma: state of the art Leukemia 2002; 16:2004-2015
11. Reff M, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-445 (Pubitemid 24030569)
12. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. Blood 1987; 69:584-591 (Pubitemid 17022032)
13. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104:1793-1800 (Pubitemid 39202289)
14. Beum PV, Lindorfer MA, Beurskens F, Stukenberg PT, Lokhorst HM, Pawluczkowycz AW, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008; 181:822-832
15. Dechant M, Teeling J, Beyer T, Roland R, Kunzendork U, Glennie MJ, et al. Novel fully human CD20 antibodies with different mechanisms of action. Blood 2003; 102:11.
16. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177:362-371
17. Bleeker WK, Munk ME, Mackus WJ, van den Brakel JH, Pluyter M, Glennie MJ, et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol 2008; 140:303-312
18. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111:1094-1100 (Pubitemid 351213387)
19. Osterborg A, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmen A, et al. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial. Blood 2008; 112:328.
20. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008; 111:5486-5495
21. Ostergaard M, Wiell C, Dawes PT, Rigby W, Petersen J, Kastberg H, et al. First clinical results of HuMax-CD20 fully human monoclonal IGG1 antibody treatment in rheumatoid arthritis. Annals Rheu Dis 2007; 65.
22. Ostergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Petersen J, et al. Ofatumumab (HuMax-CD20), a fully human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis. Early results from an ongoing, double-blind, randomized, placebo controlled clinical trial. Annals of the Rheumatic Diseases 2007; 66:124.